The money will support efforts to develop and make generic versions of what could become the first oral antiviral medication for the disease if it wins regulatory approval, the foundation said in a statement.

“Today’s commitment will ensure that more people in more countries get access to the promising drug molnupiravir, but it’s not the end of the story – we need other donors, including foundations and governments, to act,” Co-Chair Melinda French Gates said.

Merck is developing the antiviral pill along with partner Ridgeback Biotherapeutics, to treat coronavirus infections that range from mild to moderate in severity and sought U.S. emergency use authorisation for the drug this month.

The step comes as low- and middle-income countries struggle to secure life-saving vaccines and treatments for COVID-19, particularly in Africa, where just about 5% of the population is immunised.

On Tuesday, Reuters reported that an effort led by the World Health Organization to win fair access for poorer countries aims to get antiviral drugs for as little as $10 per course for people with mild symptoms.

Merck’s drug is likely to be one of them.

Launched in 2000, the non-profit Bill & Melinda Gates Foundation is the United States’ largest private philanthropic foundation and one of the world’s biggest, pouring about $1.9 billion into the fight against the pandemic since last year.

More than 241.58 million people have been reported infected with the coronavirus worldwide, and more than 5.1 million have died, a Reuters tally shows. (Reporting by Bhargav Acharya in Bengaluru; Editing by Clarence Fernandez).

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]